Photo: First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

  • The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
  • Takeda’s manufacturing site at Lessines, Belgium, is contributing to the production of the clinical material for the NIH Phase 3 trial, emphasizing the importance of Belgium as a pharmaceutical hub.

Read the rest of this article in our digital newsletter


新着ニュース


スポンサー会員

AGC GLASS EUROPE
BARCO
DAIKIN EUROPE
Deloitte
GROUP S
H. DE BEUKELAER & CO.
HONDA MOTOR EUROPE LOGISTICS NV
LIEDEKERKE
LINKLATERS LLP
MITSUI & CO BENELUX S.A./N.V.
NIPPON GASES
NTT DATA
SUMITOMO BENELUX
TAKEDA BELGIUM
TOKAI OPTECS
TOKYO ELECTRON EUROPE
TOYOTA MOTOR EUROPE
UMICORE
VIALTO PARTNERS
WILMERHALE (WILMER CUTLER PICKERING HALE AND DORR LLP)